Adagene Inc.
ADAGNasdaq
$3.59
↑ +0.3%Jul 17 close · end-of-day
Price
1Y↑ +82.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$211.8M
Enterprise Value
$139.2M
P/E
—
P/S
27.6
P/B
6.0
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$7.7M
Net Income (TTM)
-$17.6M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-279.5%
Net Margin
—
ROE
—
ROIC
—
Debt / Equity
0.1
Net Cash
$72.7M
Return 1Y
+112.4%
Company profile
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 mAb that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma.
- CEO
- Pei Z. Luo
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 260
- Website
- adagene.com
Earnings
No reported earnings periods on file.
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $700,913.00 | $10.2M | $9.3M | $18.1M | $103,204.00 | $7.7M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$43.2M | -$72.4M | -$83.9M | -$23.7M | -$36.0M | -$21.4M |
| Net income | -$42.4M | -$73.2M | -$80.0M | -$18.9M | -$33.4M | -$17.6M |
| Diluted EPS | -$2.67 | -$1.46 | -$1.48 | -$0.35 | -$0.59 | -$0.30 |
| Operating cash flow | -$28.5M | -$43.4M | -$48.6M | -$28.5M | -$29.7M | -$15.7M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -6156.5% | -711.2% | -903.1% | -131.0% | -34835.4% | -279.5% |
| Net margin | -6048.9% | -719.2% | -860.6% | -104.6% | -32386.4% | -229.6% |
No quarterly data.
Company news
May 19, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.